Since the last ACC/AHA cholesterol guidelines in 2018, the FDA has approved new non-statin cholesterol medications, which have increased our ability to provide a broader range of lipid-lowering drugs. In this podcast, we will discuss the new 2022 ACC expert consensus decision pathway on the role of non-statin therapies for LDL lowering in managing atherosclerotic cardiovascular disease risk. We will review these new drugs and discuss which ones to consider, when, and in what order.

Topics Discussed:
• What are these new FDA-approved nonstatin drugs for lipid-lowering?To whom and when non-statins should be considered?
• Are there new LDL targets or thresholds for certain patients?
• What are the new guideline recommendations for patients with statin intolerance?

свернуть